Patient Enrollment Completed for CARDINAL Study Testing Bardoxolone for Improving Kidney Function

Reata Pharmaceuticals has completed patient enrollment for Phase 3 of its CARDINAL study investigating the safety and efficacy of bardoxolone methyl (bardoxolone) for improving kidney function in people with Alport syndrome, the company announced. The Phase 3 part of the CARDINAL trial (NCT03019185), which has enrolled…